Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 883 for:    Liver Transplant

Everolimus Post Orthotopic Liver Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01998789
Recruitment Status : Recruiting
First Posted : December 2, 2013
Last Update Posted : August 10, 2017
Sponsor:
Information provided by (Responsible Party):
Tomoaki Kato, Columbia University

Brief Summary:
The purpose of this study is to evaluate the efficacy of an everolimus conversion (EVR) protocol as compared to the standard tacrolimus (TAC) based protocol in liver transplant recipients, as determined by renal function, rejection rates, and progression to fibrosis (in HCV positive subjects). Additionally, safety profile and tolerability of these regimens will be assessed.

Condition or disease Intervention/treatment Phase
Orthotopic Liver Transplant Drug: Everolimus Drug: Standard Tacrolimus Phase 2

Detailed Description:

The mainstay of maintenance immunosuppression post-transplantation includes a calcineurin inhibitor, either cyclosporine or tacrolimus. The introduction of calcineurin inhibitors led to a significant improvement in graft and patient outcomes post solid organ transplantation. However, one of the severe limitations of this class of drugs, is its associated nephrotoxicity. Data from the Scientific Registry of Transplant Recipients reveal that the incidence of stage 4 chronic kidney disease or stage 5 Chronic Kidney Disease (CKD) after Orthotopic Liver Transplantation (OLT) at 1, 3, and 5 years is 8%, 14%, and 18%, respectively, increasing to approximately 25% by 10 years after transplantation.Furthermore, renal dysfunction is associated with a four-fold increase in patient mortality post solid organ transplantation.

Several calcineurin inhibitor sparing and minimizing regimens have been studied. Most recently, in the phase III, randomized study in de novo liver transplant recipients,demonstrated significantly improved renal function in the tacrolimus minimization arm (everolimus plus tacrolimus one year post transplant.In fact superior renal function was achieved with the tacrolimus minimization arm one month after randomization and was maintained to Month 12. With this pilot study, we aim to compare the efficacy of the standard immunosupression post liver transplant with Tacrolimus and Mycophenolic acid (Myfortic)with calcineurin sparing regimen using the combination of everolimus and enteric coated mycophenolic acid, as determined by the estimated Glomerular filtration rate (GFR) at one year post transplant, with acceptable rates of biopsy proven rejection.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Open-label, Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Everolimus Conversion Versus Standard Immunosuppression in Liver Transplant Recipients
Study Start Date : October 2013
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Everolimus Conversion Arm

Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.

Everolimus doses will be adjusted based on local lab results of everolimus trough levels.

Drug: Everolimus
Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
Other Name: Zortress

Active Comparator: Standard Tacrolimus Immunosuppresion Arm

Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.

Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels.

Drug: Standard Tacrolimus

Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.

Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels.

Other Name: Prograf




Primary Outcome Measures :
  1. Change in estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Baseline and 12 months post transplant ]
    Comparison of change in Renal function, as measured by eGFR from baseline to 12 months post liver transplantation, in subjects maintained on an everolimus conversion regimen versus those maintained on a standard tacrolimus based regimen.


Secondary Outcome Measures :
  1. Change in estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Baseline and 24 months post liver transplantation ]
    1. Comparison of renal function, as measured eGFR from baseline to 24 months post liver transplantation, in subjects maintained on an everolimus conversion regimen versus those maintained on a standard tacrolimus based regimen.
    2. To compare the incidence of renal insufficiency, defined as GFR<30 or need for dialysis at 12 months and 24 months post liver transplantation, in subjects maintained on an everolimus conversion regimen versus those maintained on a standard tacrolimus based regimen.

  2. Proportion of HCV patients who develop stage 2 of 4 or greater fibrosis, liver failure, or fibrosing cholestatic hepatitis (FCH) at month 12 and 24 [ Time Frame: Up to 24 months post liver transplantation ]

    To determine whether everolimus conversion post liver transplantation reduces progression of fibrosis at 12 and 24 months post transplant as compared to standard tacrolimus based immunosuppression in liver transplant recipients with Hepatitis C as measured by:

    Proportion of patients who develop stage 2 of 4 or greater fibrosis, liver failure, or fibrosing cholestatic hepatitis (FCH) at month 12 and 24


  3. Composite Efficacy Failure Rate [ Time Frame: Up to 24 months ]

    To compare the composite efficacy failure rates of treated biopsy proven acute rejection, graft loss, death, or loss to follow up with Everolimus conversion arm to standard immunosuppression with Tacrolimus based arm at 12 and 24 months after liver transplant.

    To compare each component of the composite efficacy failure rates between Everolimus conversion and standard Tacrolimus arm.

    To compare the composite graft failure or death or loss of follow up between the two arms.

    To Evaluate acute rejection by incidence, time to interval and severity.


  4. Incidence of Hepatocellular Carcinoma (HCC) Recurrence [ Time Frame: Up to 12 months post transplant ]
    In subjects with Hepatocellular carcinoma (HCC), to compare the incidence of HCC recurrence at 12 months post transplantation between the Everolimus conversion arm and the standard tacrolimus based arm, as evaluated by radiological studies, biopsy findings, and/or AFP levels.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability and willingness to provide informed consent and adhere to study regimen
  • Recipients of primary liver transplant from deceased or living donor
  • 18 years of age or greater
  • Lab Model For End-Stage Liver Disease (MELD) score ≤ 30
  • Abbreviated Modification of Diet in Renal Disease (MDRD) eGFR ≥ 30 mL/min/1.73

Key Exclusion Criteria:

  • Recipient of multiple solid or organ transplant, or have previously received and organ transplant
  • Women of child-bearing potential unless they are willing to participate in adequate contraception methods as outlined in the study.
  • HIV infection (results obtained 6 months prior to screening is acceptable)

Key Exclusion-Baseline/ Randamization

  • Severe hypercholesterolemia (> 350 mg/dL) or hypertriglyceridemia (> 500 mg/dL) within 30 days prior to baseline.
  • Thrombocytopenia (platelets < 50,000/mm3)
  • Absolute neutrophil count of < 1000/mm3 or white blood cell count of < 2000/mm3
  • Subjects in a critical care unit requiring life support measures such as mechanical ventilation, dialysis, requirement of vasopressor agents
  • Liver allograft is functioning at an unacceptable level as defined by the Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Total Bilirubin levels > 3 times upper limit of normal (ULN) and Alkaline Phosphatase (AlkP) and Gamma-glutamyltransferase (GGT) levels > 5 times ULN
  • Diagnosis of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis
  • Hepatocellular carcinoma with evidence of macrovascular invasion on explanted liver or evidence of extrahepatic spread
  • Inability to take medications by mouth
  • Renal insufficiency, as defined by abbreviated MDRD eGFR < 30 mL/min/1.73m2, or requirement of dialysis, that does not recover prior to baseline
  • Episode of acute rejection requiring antibody therapy or more than one steroid treated episode of acute rejection
  • Subjects with a confirmed spot urine protein/creatinine ratio that indicates ≥1g/24h of proteinuria.
  • Subtherapeutic trough levels of tacrolimus during the week prior to baseline (subject must have at least one tacrolimus level ≥ 8 ng/mL)
  • The presence of thrombosis via Doppler ultrasound of the major hepatic arteries, major hepatic veins, portal vein and inferior vena cava.
  • Presence of clinically significant wound

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01998789


Contacts
Layout table for location contacts
Contact: Theresa Lukose, PharmD tt2103@columbia.edu
Contact: Marcela Laurito, MD 212-305-3839 ml3727@cumc.columbia.edu

Locations
Layout table for location information
United States, New York
Columbia University Medical Center-NYPH Recruiting
New York, New York, United States, 10032
Contact: Tomoaki Kato, M.D       tk2388@columbia.edu   
Contact: Theresa Lukose, PharmD       tt2103@columbia.edu   
Principal Investigator: Tomoaki Kato, MD         
Sponsors and Collaborators
Tomoaki Kato
Investigators
Layout table for investigator information
Principal Investigator: Tomoaki Kato, MD Columbia University

Layout table for additonal information
Responsible Party: Tomoaki Kato, Chief, Division of Abdominal Organ Transplantation, Columbia University
ClinicalTrials.gov Identifier: NCT01998789     History of Changes
Other Study ID Numbers: AAAL1602
First Posted: December 2, 2013    Key Record Dates
Last Update Posted: August 10, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Tomoaki Kato, Columbia University:
Liver Transplantation
Everolimus
Immunosuppression

Additional relevant MeSH terms:
Layout table for MeSH terms
Tacrolimus
Everolimus
Sirolimus
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antibiotics, Antitubercular
Antitubercular Agents